COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN
Publication date
2018-10-01
Authors
Vreman, R.
van Nuland, M.
ten Ham, R.M.
de Vries-Schultink, A.H.
Rosing, H.
Schellens, Johannes
Beijnen, Jos
Hovels, A.M.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
adjuvant, endogenous compound, endoxifen, estrogen receptor alpha, tamoxifen, adult, breast cancer, cancer adjuvant therapy, cancer patient, cancer recurrence, cancer survival, clinician, conference abstract, controlled study, cost effectiveness analysis, death, diagnostic test accuracy study, disease free survival, drug efficacy, drug monitoring, drug therapy, female, human, human tissue, major clinical study, Netherlands, probability, quality adjusted life year, sensitivity analysis, Taverne, SDG 3 - Good Health and Well-being
Citation
Vreman, R, van Nuland, M, ten Ham, R M, de Vries-Schultink, A H, Rosing, H, Schellens, J H, Beijnen, J H & Hovels, A M 2018, 'COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN', Value in Health, vol. 21, no. Supplement 3, pp. S46-S46. https://doi.org/10.1016/j.jval.2018.09.273